Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
This access model supports clinical efficiency and research workflows
Why this trial matters: Provides real-world evidence on first-line regimens in a poor-prognosis mCRC subtype Highlights superior survival with chemo + anti-VEGF versus chemo alone or targeted therapy Reinforces the importance of personalized treatment strategies and further trials Eli Lilly Retatrutide Delivers Unprecedented Weight Loss in Phase III TRIUMPH-4 Trial Eli Lillys investigational triple-agonist retatrutide produced an average ~28.7% body-weight reduction (71.2 lbs) at 68 weeks in the Phase III TRIUMPH-4 obesity trial, along with meaningful knee osteoarthritis pain relief, marking one of the strongest weight-loss results reported in late-stage obesity research
It is not medical advice, and the compounds discussed are intended for laboratory research use only
10.1007/s11926-016-0617-5 81
References: Bendotti G, Montefusco L, Lunati ME, et al
